Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations

Michael N. Mongelli, Benjamin J. Peipert, Sneha Goswami, Irene Helenowski, Susan Yount, Cord Sturgeon*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: Patient-reported outcomes are measured in chronic disease states to inform intervention and management decisions while minimizing negative outcomes. We hypothesized that health-related quality of life in patients with multiple endocrine neoplasia type 2A would be worse than the general US population but similar to other chronic diseases. Methods: Adults ≥18 years with multiple endocrine neoplasia type 2A were recruited to complete the Patient-Reported Outcomes Measurement Information System 29-item questionnaire (n = 45). Scores based on the Patient-Reported Outcomes Measurement Information System T-score metric were compared with the general US population and with cohorts with low back pain, cancer, congestive heart failure, chronic obstructive pulmonary disease, major depressive disorder, rheumatoid arthritis, neuroendocrine tumors, primary hyperparathyroidism, and MEN1. Results: Compared with US normative data, multiple endocrine neoplasia type 2A patients reported worse anxiety (58.2 ± 12.0, P <.0001), depression (55.4 ± 12.0, P <.01), fatigue (61.4 ± 10.8, P <.0001), pain interference (54.0 ± 11.5, P <.05), and sleep disturbance (56.9 ± 2.7, P <.001), as well as significantly lower physical functioning (45.7 ± 9.3, P <.01) and ability to participate in social roles (46.4 ± 9.7, P <.05). Multiple endocrine neoplasia type 2A patients reported greater fatigue than patients with cancer (P <.0001), chronic obstructive pulmonary disease (P =.01), rheumatoid arthritis (P =.0002), neuroendocrine tumors (P =.0007), and primary hyperparathyroidism (P <.0001) but higher physical functioning compared with patients with rheumatoid arthritis (P =.02), low back pain, congestive heart failure, and chronic obstructive pulmonary disease (P <.0001). Conclusions: This study is the first to use the Patient-Reported Outcomes Measurement Information System to compare patient-reported outcomes between multiple endocrine neoplasia type 2A and other chronic conditions. Individuals with multiple endocrine neoplasia type 2A reported worse health-related quality of life in all 7 domains compared with US normative data. Multiple endocrine neoplasia type 2A patients reported greater fatigue but greater physical function compared with several other conditions. Prospective longitudinal evaluation of patient-reported outcomes in multiple endocrine neoplasia type 2A should be conducted to identify treatments associated with the highest health-related quality of life.

Original languageEnglish (US)
Pages (from-to)546-552
Number of pages7
JournalSurgery (United States)
Volume164
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Multiple Endocrine Neoplasia Type 2a
Quality of Life
Population
Information Systems
Chronic Obstructive Pulmonary Disease
Fatigue
Rheumatoid Arthritis
Neuroendocrine Tumors
Primary Hyperparathyroidism
Low Back Pain
Chronic Disease
Heart Failure
Multiple Endocrine Neoplasia Type 1
Aptitude
Major Depressive Disorder
Patient Reported Outcome Measures
Neoplasms
Sleep
Anxiety
Depression

ASJC Scopus subject areas

  • Surgery

Cite this

Mongelli, Michael N. ; Peipert, Benjamin J. ; Goswami, Sneha ; Helenowski, Irene ; Yount, Susan ; Sturgeon, Cord. / Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations. In: Surgery (United States). 2018 ; Vol. 164, No. 3. pp. 546-552.
@article{ff6c0f9426854615a8996138930fff6a,
title = "Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations",
abstract = "Background: Patient-reported outcomes are measured in chronic disease states to inform intervention and management decisions while minimizing negative outcomes. We hypothesized that health-related quality of life in patients with multiple endocrine neoplasia type 2A would be worse than the general US population but similar to other chronic diseases. Methods: Adults ≥18 years with multiple endocrine neoplasia type 2A were recruited to complete the Patient-Reported Outcomes Measurement Information System 29-item questionnaire (n = 45). Scores based on the Patient-Reported Outcomes Measurement Information System T-score metric were compared with the general US population and with cohorts with low back pain, cancer, congestive heart failure, chronic obstructive pulmonary disease, major depressive disorder, rheumatoid arthritis, neuroendocrine tumors, primary hyperparathyroidism, and MEN1. Results: Compared with US normative data, multiple endocrine neoplasia type 2A patients reported worse anxiety (58.2 ± 12.0, P <.0001), depression (55.4 ± 12.0, P <.01), fatigue (61.4 ± 10.8, P <.0001), pain interference (54.0 ± 11.5, P <.05), and sleep disturbance (56.9 ± 2.7, P <.001), as well as significantly lower physical functioning (45.7 ± 9.3, P <.01) and ability to participate in social roles (46.4 ± 9.7, P <.05). Multiple endocrine neoplasia type 2A patients reported greater fatigue than patients with cancer (P <.0001), chronic obstructive pulmonary disease (P =.01), rheumatoid arthritis (P =.0002), neuroendocrine tumors (P =.0007), and primary hyperparathyroidism (P <.0001) but higher physical functioning compared with patients with rheumatoid arthritis (P =.02), low back pain, congestive heart failure, and chronic obstructive pulmonary disease (P <.0001). Conclusions: This study is the first to use the Patient-Reported Outcomes Measurement Information System to compare patient-reported outcomes between multiple endocrine neoplasia type 2A and other chronic conditions. Individuals with multiple endocrine neoplasia type 2A reported worse health-related quality of life in all 7 domains compared with US normative data. Multiple endocrine neoplasia type 2A patients reported greater fatigue but greater physical function compared with several other conditions. Prospective longitudinal evaluation of patient-reported outcomes in multiple endocrine neoplasia type 2A should be conducted to identify treatments associated with the highest health-related quality of life.",
author = "Mongelli, {Michael N.} and Peipert, {Benjamin J.} and Sneha Goswami and Irene Helenowski and Susan Yount and Cord Sturgeon",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.surg.2018.04.036",
language = "English (US)",
volume = "164",
pages = "546--552",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations. / Mongelli, Michael N.; Peipert, Benjamin J.; Goswami, Sneha; Helenowski, Irene; Yount, Susan; Sturgeon, Cord.

In: Surgery (United States), Vol. 164, No. 3, 01.09.2018, p. 546-552.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations

AU - Mongelli, Michael N.

AU - Peipert, Benjamin J.

AU - Goswami, Sneha

AU - Helenowski, Irene

AU - Yount, Susan

AU - Sturgeon, Cord

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Patient-reported outcomes are measured in chronic disease states to inform intervention and management decisions while minimizing negative outcomes. We hypothesized that health-related quality of life in patients with multiple endocrine neoplasia type 2A would be worse than the general US population but similar to other chronic diseases. Methods: Adults ≥18 years with multiple endocrine neoplasia type 2A were recruited to complete the Patient-Reported Outcomes Measurement Information System 29-item questionnaire (n = 45). Scores based on the Patient-Reported Outcomes Measurement Information System T-score metric were compared with the general US population and with cohorts with low back pain, cancer, congestive heart failure, chronic obstructive pulmonary disease, major depressive disorder, rheumatoid arthritis, neuroendocrine tumors, primary hyperparathyroidism, and MEN1. Results: Compared with US normative data, multiple endocrine neoplasia type 2A patients reported worse anxiety (58.2 ± 12.0, P <.0001), depression (55.4 ± 12.0, P <.01), fatigue (61.4 ± 10.8, P <.0001), pain interference (54.0 ± 11.5, P <.05), and sleep disturbance (56.9 ± 2.7, P <.001), as well as significantly lower physical functioning (45.7 ± 9.3, P <.01) and ability to participate in social roles (46.4 ± 9.7, P <.05). Multiple endocrine neoplasia type 2A patients reported greater fatigue than patients with cancer (P <.0001), chronic obstructive pulmonary disease (P =.01), rheumatoid arthritis (P =.0002), neuroendocrine tumors (P =.0007), and primary hyperparathyroidism (P <.0001) but higher physical functioning compared with patients with rheumatoid arthritis (P =.02), low back pain, congestive heart failure, and chronic obstructive pulmonary disease (P <.0001). Conclusions: This study is the first to use the Patient-Reported Outcomes Measurement Information System to compare patient-reported outcomes between multiple endocrine neoplasia type 2A and other chronic conditions. Individuals with multiple endocrine neoplasia type 2A reported worse health-related quality of life in all 7 domains compared with US normative data. Multiple endocrine neoplasia type 2A patients reported greater fatigue but greater physical function compared with several other conditions. Prospective longitudinal evaluation of patient-reported outcomes in multiple endocrine neoplasia type 2A should be conducted to identify treatments associated with the highest health-related quality of life.

AB - Background: Patient-reported outcomes are measured in chronic disease states to inform intervention and management decisions while minimizing negative outcomes. We hypothesized that health-related quality of life in patients with multiple endocrine neoplasia type 2A would be worse than the general US population but similar to other chronic diseases. Methods: Adults ≥18 years with multiple endocrine neoplasia type 2A were recruited to complete the Patient-Reported Outcomes Measurement Information System 29-item questionnaire (n = 45). Scores based on the Patient-Reported Outcomes Measurement Information System T-score metric were compared with the general US population and with cohorts with low back pain, cancer, congestive heart failure, chronic obstructive pulmonary disease, major depressive disorder, rheumatoid arthritis, neuroendocrine tumors, primary hyperparathyroidism, and MEN1. Results: Compared with US normative data, multiple endocrine neoplasia type 2A patients reported worse anxiety (58.2 ± 12.0, P <.0001), depression (55.4 ± 12.0, P <.01), fatigue (61.4 ± 10.8, P <.0001), pain interference (54.0 ± 11.5, P <.05), and sleep disturbance (56.9 ± 2.7, P <.001), as well as significantly lower physical functioning (45.7 ± 9.3, P <.01) and ability to participate in social roles (46.4 ± 9.7, P <.05). Multiple endocrine neoplasia type 2A patients reported greater fatigue than patients with cancer (P <.0001), chronic obstructive pulmonary disease (P =.01), rheumatoid arthritis (P =.0002), neuroendocrine tumors (P =.0007), and primary hyperparathyroidism (P <.0001) but higher physical functioning compared with patients with rheumatoid arthritis (P =.02), low back pain, congestive heart failure, and chronic obstructive pulmonary disease (P <.0001). Conclusions: This study is the first to use the Patient-Reported Outcomes Measurement Information System to compare patient-reported outcomes between multiple endocrine neoplasia type 2A and other chronic conditions. Individuals with multiple endocrine neoplasia type 2A reported worse health-related quality of life in all 7 domains compared with US normative data. Multiple endocrine neoplasia type 2A patients reported greater fatigue but greater physical function compared with several other conditions. Prospective longitudinal evaluation of patient-reported outcomes in multiple endocrine neoplasia type 2A should be conducted to identify treatments associated with the highest health-related quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85048477355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048477355&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2018.04.036

DO - 10.1016/j.surg.2018.04.036

M3 - Article

VL - 164

SP - 546

EP - 552

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3

ER -